Genogenic immunohistochemistry: A new era in diagnostic immunohistochemistry

Current Diagnostic Pathology

Volumn 8, Issue 3, 2002, Pages 193-200

  Gown, A M ^a,b  

^a PHENOPATH LABORATORIES   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anaplastic large cell lymphoma; Breast cancer; Desmoplastic small round cell tumour; Hereditary non polyposis colon cancer; Immunohistochemistry; PNET Ewings sarcoma

Indexed keywords

ALK PROTEIN; BCR ABL PROTEIN; IMATINIB; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN;

ANAPLASTIC CARCINOMA; BREAST CANCER; CHROMOSOME TRANSLOCATION; COLON CANCER; EWING SARCOMA; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; ONCOGENE NEU; POLYMERASE CHAIN REACTION; REVIEW; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0036620278     PISSN: 09686053     EISSN: None     Source Type: Journal    
DOI: 10.1054/cdip.2002.0116     Document Type: Review

References (62)

1. Coons A H, Creech H J, Jones R N. Immunological properties of an antibody containing a fluorescent group. Proc Soc Exp Biol 1941; 47: 200-202.
2. Moll R, Mitze M, Frixen U H, Birchmeier W. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol 1993; 143: 1731-1742.
3. Lehr H A, Folpe A, Yaziji H, Kommoss F, Gown A M. Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. Am J Clin Pathol 2000; 114: 190-196.
4. Kanai Y, Oda T, Tsuda H, Ochiai A, Hirohashi S. Point mutation of the E-cadherin gene in invasive lobular carcinoma of the breast. Jpn J Cancer Res 1994; 85: 1035-1039.
5. Berx G, Cleton J-A M, Strumane K, de L-WJ, Nollet F, van R-F et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996; 13: 1919-1925.
6. Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart I R. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 2001; 92: 404-408.
7. Vos C B, Cleton J-A M, Berx G, de L-W J, ter H-N T, van R-F et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumourigenesis. Br J Cancer 1997; 76: 1131-1133.
8. Goldstein N S, Bassi D, Watts J C, Layfield L J, Yaziji H, Gown A M. E-cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the interpretation of problematic lesions. Am J Clin Pathol 2001; 115: 534-542.
9. Jacobs T W, Pliss N, Kouria G, Schnitt S J. Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. Am J Surg Pathol 2001; 25: 229-236.
10. Goldstein N S, Kestin L L, Vicini F A. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Cancer 2001; 92: 738-747.
11. Fearon E R, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
12. Marra G, Boland C R. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995; 87: 1114-1125.
13. Peltomaki P, de la Chapelle A. Mutations predisposing to hereditary nonpolyposis colorectal cancer. Adv Cancer Res 1997; 71: 93-119.
14. Jass J R. Pathology of hereditary nonpolyposis colorectal cancer. Ann NY Acad Sci 2000; 910: 62-73; discussion 73-74.
15. Loeb L A. Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 1994; 54: 5059-5063.
16. Loeb L A. A mutator phenotype in cancer. Cancer Res 2001; 61: 3230-3239.
17. Kim H, Piao Z, Kim J W, Choi J S, Kim N K, Lee J M et al. Expression of hMSH2 and hMLH1 in colorectal carcinomas with microsatellite instability. Pathol Res Practice 1998; 194: 3-9.
18. Cawkwell L, Gray S, Murgatroyd H, Sutherland F, Haine L, Longfellow M et al. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair [see comments]. Gut 1999; 45: 409-415.
19. Rimokh R, Magaud J P, Berger F, Samarut J, Coiffier B, Germain D et al. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma'). Br J Haematol 1989; 71: 31-36.
20. Morris S W, Kirstein M N, Valentine M B, Dittmer KG, Shapiro D N, Saltman D L et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-1284.
21. Downing J R, Shurtleff S A, Zielenska M, Curcio-Brint A M, Behm F G, Head D R et al. Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction. Blood 1995; 85: 3416-3422.
22. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 1995; 86: 1954-1960.
23. Pittaluga S, Wiodarska I, Pulford K, Campo E, Morris S W, Van d-B-H et al. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol 1997; 151: 343-351.
24. Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier-Lacombe M J et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998; 91: 2076-2084.
25. Falini B, Pulford K, Pucciarini A, Carbone A, De Wolf-Peeters C, Cordell J et al. Lymphomas expressing ALK fusion protein (s) other than NPM-ALK. Blood 1999; 94: 3509-3515.
26. Downing J R, Head D R, Parham D M, Douglass E C, Hulshof M G, Link M P et al. Detection of the (11;22)(q24;q12) translocation of Ewing's sarcoma and peripheral neuroectodermal tumour by reverse transcription polymerase chain reaction. Am J Pathol 1993; 143: 1294-1300.
27. Melot T, Gruel N, Doubeikovski A, Sevenet N, Teillaud JL, Delattre O. Production and characterization of mouse monoclonal antibodies to wild-type and oncogenic FLI-1 proteins. Hybridoma 1997; 16: 457-464.
28. Folpe A L, Hill C E, Parham D M, O'Shea P A, Weiss S W. Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumours with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumour. Am J Surg Pathol 2000; 24: 1657-1662.
29. Llombart-Bosch A, Navarro S. Immunohistochemical detection of EWS and FLI-1 proteins in Ewing sarcoma and primitive neuroectodermal tumours: comparative analysis with CD99 (MIC-2) expression. Appl Immunohistochem Mol Morphol 2001; 9: 255-260.
30. Gerald W L, Ladanyi M, de Alava E, Cuatrecasas M, Kushner B H, LaQuaglia M P et al. Clinical, pathologic, and molecular spectrum of tumours associated with t(11;22)(p13;q12): desmoplastic small round-cell tumour and its variants. Clin Oncol 1998; 16: 3028-3036.
31. Barnoud R, Delattre O, Pėoc'h M, Pasquier D, Plantaz D, Leroux D et al. Desmoplastic small round cell tumour: RT-PCR analysis and immunohistochemical detection of the Wilm's tumour gene WTI. Pathol Res Practice 1998; 194: 693-700.
32. Charles A K, Moore I E, Berry P J. Immunohistochemical detection of the Wilms' tumour gene WTI in desmoplastic small round cell tumour. Histopathology 1997; 30: 312-314.
33. Ordonez N G. Desmoplastic small round cell tumour: II: an ultrastructural and immunohistochemical study with emphasis on new immunohistochemical markers. Am J Surg Pathol 1998; 22: 1314-1327.
34. Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A, McGuire W L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
35. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up [see comments]. J Clin Oncol 1992; 10: 1044-1048.
36. Paik S, Hazan R, Fisher E R, Sass R E, Fisher B, Redmond C et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer [Prior annotation incorrect]. J Clin Oncol 1990; 8: 103-112.
37. Tandon A K, Clark G M, Chamness G C, Ullrich A, McGuire W L. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7: 1120-1128.
38. Muss H B, Thor A D, Berry D A, Kute T, Liu E T, Koerner F et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-1266.
39. Thor A D, Berry D A, Budman D R, Muss H B, Kute T, Henderson I C et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer [see comments]. J Natl Cancer Inst 1998; 90: 1346-1360.
40. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer [see comments]. J Natl Cancer Inst 1998; 90: 1361-1370.
41. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16: 462-469.
42. Wright C, Nicholson S, Angus B, Sainsbury J R, Farndon J, Cairns J et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65: 118-121.
43. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14: 2702-2708.
44. Tetu B, Brisson J, Plante V, Bernard P. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol 1998; 11: 823-830.
45. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 1999; 26 (4 Suppl 12): 71-77.
46. Slamon D J, Leyland Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
47. Jacobs T W, Gown A M, Yaziji H, Barnes M J, Schnitt S J. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-Approved Scoring System. J Clin Oncol 1999; 17: 1983.
48. Tubbs R R, Pettay J D, Roche P C, Stoler M H, Jenkins R B, Grogan T M. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001; 19: 2714-2721.
49. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H et al. Evaluation of the United States food and drug administration-approved scoring and test system of her-2 protein expression in breast cancer. Clin Cancer Res 2001; 7: 1669-1675.
50. Jacobs T W, Gown A M, Yaziji H, Barnes M J, Schnitt S J. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999; 17: 1974-1982.
51. Wang S, Saboorian M H, Frenkel E, Hynan L, Gokaslan S T, Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000; 53: 374-381.
52. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18: 3651-3664.
53. Kakar S, Puangsuvan N, Stevens J M, Serenas R, Mangan G, Sahai S et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn 2000; 5: 199-207.
54. Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B et al. Strong correlation between results of fluoresence in situ hybridization and immunohistochemistry for the assessment of ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 2000; 13: 1238-1243.
55. Hoang M P, Sahin A A, Ordonez N G, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000; 113: 852-859.
56. Ridolfi R L, Jamehdor M R, Arber J M. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescent in situ hybridization approach. Mod Pathol 2000; 13: 866-873.
57. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B et al. HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001; 19: 354-363.
58. Buchdunger E, Matter A, Druker B J. Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta 2001; 1551: M11-M18.
59. O'Dwyer M E, Druker B J. Chronic myelogenous leukaemia-new therapeutic principles. J Intern Med 2001; 250: 3-9.
60. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed R K, Heldin C H et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumours. Cancer Res 2001; 61: 2929-2934.
61. Joensuu H, Roberts P J, Sarlomo-Rikala M, Andersson L C, Tervahartiala P, Tuveson D et al. Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056.
62. Berman J, O'Leary T J. Gastrointestinal stromal tumor workshop. Hum Pathol 2001; 32: 578-582.